Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$105.07
$0.720.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 432.16M | 385.69M | 338.46M | 291.49M | 251.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 432.16M | 385.69M | 338.46M | 291.49M | 251.02M |
| Cost of Revenue | 36.80M | 33.30M | 30.17M | 28.26M | 24.81M |
| Gross Profit | 395.36M | 352.39M | 308.29M | 263.23M | 226.22M |
| SG&A Expenses | 433.18M | 411.36M | 384.90M | 372.52M | 347.90M |
| Depreciation & Amortization | 6.38M | 6.39M | 6.39M | 6.39M | 6.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 671.38M | 638.13M | 584.33M | 553.43M | 496.08M |
| Operating Income | -239.22M | -252.44M | -245.87M | -261.94M | -245.06M |
| Income Before Tax | -278.19M | -287.13M | -311.28M | -309.56M | -298.00M |
| Income Tax Expenses | 85.00K | 85.00K | -325.00K | -1.00M | -1.62M |
| Earnings from Continuing Operations | -278.27 | -287.22 | -310.96 | -308.55 | -296.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -278.27M | -287.22M | -310.96M | -308.55M | -296.38M |
| EBIT | -239.22M | -252.44M | -245.87M | -261.94M | -245.06M |
| EBITDA | -230.85M | -244.37M | -238.14M | -254.52M | -238.06M |
| EPS Basic | -5.77 | -6.00 | -6.54 | -6.51 | -6.38 |
| Normalized Basic EPS | -3.20 | -3.38 | -3.30 | -3.51 | -3.38 |
| EPS Diluted | -5.77 | -6.00 | -6.54 | -6.51 | -6.38 |
| Normalized Diluted EPS | -3.20 | -3.38 | -3.30 | -3.51 | -3.38 |
| Average Basic Shares Outstanding | 193.13M | 191.65M | 190.44M | 189.41M | 185.51M |
| Average Diluted Shares Outstanding | 193.13M | 191.65M | 190.44M | 189.41M | 185.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |